AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an upbeat note about its prospects for the year ahead.
The UK-headquartered drugmaker on Tuesday said revenue increased 8 per cent last year to $58.7bn, driven by a 14 per cent increase in sales of cancer medications and 12 per cent growth in respiratory and immunology medicines.
Core earnings per share, a key industry profit metric, were $9.16, an 11 per cent increase on 2024.
您已阅读21%（498字），剩余79%（1855字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。